Global Hepatitis D Virus (HDV) Infection Market is Expected to Gain Remarkable Growth over the Forecast Period

Global Hepatitis D Virus (HDV) Infection Market to grow at a CAGR of 3% by 2030 : Absolute Markets Insights

PUNE, MAHARASHTRA, INDIA, March 14, 2022 /EINPresswire.com/ -- The rapidly aging global population, as well as extensive research and development activities in emerging economies, are driving the global hepatitis D Virus (HDV) infection market. Infection with Hepatitis Delta Virus causes Hepatitis Delta, the most severe form of viral hepatitis. HDV is only found as a co-infection in people infected with Hepatitis B Virus (HBV). Chronic Hepatitis D virus (HDV) infection is a worldwide problem that causes rapidly progressive liver disease, increased liver-related mortality, and hepatocellular carcinoma. According to reports, current estimates indicate that HDV co-infection is present in 15-20 million people worldwide with HBV infection, but new data suggests that this figure underestimates the true prevalence of coinfections.

Get PDF sample report with related graphs & charts (Pre & post COVID-19 impact analysis): https://www.absolutemarketsinsights.com/request_sample.php?id=1087

There are some major companies that are in the drug development phase and are expected to contribute for the hepatitis D Virus (HDV) infection market growth. For instance, Eiger BioPharmaceuticals, Inc., a company focused on the development and commercialization of therapeutic targets for rare and ultra-rare diseases, announced that the Food and Drug Administration (FDA) had granted breakthrough therapy designation for lonafarnib for the treatment of hepatitis delta virus (HDV) infection in December 2018. Lonafarnib has received Orphan Drug Designation from the US FDA and the European Medicines Agency (EMA), as well as fast track and breakthrough therapy designation from the US FDA and PRIME designation from the EMA. Lonafarnib is an oral medication in development for HDV. Lonafarnib inhibits the prenylation step of HDV replication within liver cells, effectively blocking the virus's life cycle at the assembly stage.

The detailed research study provides qualitative and quantitative analysis of hepatitis D virus (HDV) infection market. The market has been analyzed from demand as well as supply side. The demand side analysis covers market revenue across regions and further across all the major countries. The supply side analysis covers the major market players and their regional and global presence and strategies. The geographical analysis done emphasizes on each of the major countries across North America, Europe, Asia Pacific, Middle East & Africa and Latin America.

Speak to our analyst in case of queries before buying this report: https://www.absolutemarketsinsights.com/enquiry_before_buying.php?id=1087

Key Findings of the Report:
• Pre-Clinical and Phase I segment accounted for the highest share, due to increased funding from government and public-private organizations. Most companies are in the early stages of developing a drug to treat hepatitis D virus (HDV) infection.
• Acute HDV superinfection of a chronic HBV carrier holds a significant share of the market. HDV superinfection can expedite the progression of an existing HBV infection, resulting in liver cirrhosis and failure. HDV superinfection accelerates the progression of chronic HBV in 70–90% of people, regardless of age. Although HDV inhibits HBV replication, cirrhosis occurs up to a decade earlier in HDV-superinfected people than infected people in HBV alone.
• Hepatitis D infects approximately 12 million people worldwide. Co-infection of hepatitis B virus (HBV) with HDV in adults is usually self-limiting, but it can also be associated with a severe form of acute hepatitis and can progress to fulminant hepatitis. According to the World Health Organization (WHO), HDV superinfection on chronic hepatitis B accelerates disease progression in all ages and in 70-90 percent of people.
• Growing research activities across the globe contribute for the highest share of the research center segment in the hepatitis D virus (HDV) infection market.
• Asia Pacific region is expected to be the fastest growing region in the global hepatitis D virus (HDV) infection market over the forecast period. Increasing population, increasing adoption of advanced technology, and favorable government policies for new drug development are factors driving the growth of the Asia Pacific hepatitis D virus (HDV) infection market over the forecast period. Furthermore, major economies such as China, India, and Japan are making significant contributions to the development of healthcare infrastructure in this region, which is driving the market growth. According to data from the National Library of Medicine, the Asia-Pacific region now appears to be where HDV is of a major health concern. The majority of South Asian countries have favorable conditions for the spread of hepatitis B and other related infections. HDV prevalence has increased over time in countries such as Pakistan and Iran. Other countries and regions, such as China, Turkey, Australia, Japan, India, and Taiwan, which had historically high HDV prevalence, have seen a decrease in incidence, but high prevalence persists in some.

Some of the players operating in the hepatitis D virus (HDV) infection market:
• Alnylam Pharmaceuticals, Inc.
• EigerBioPharmaceuticals
• Gilead Sciences, Inc.
• Janssen Global Services, LLC
• Replicor
• Other Market participants

Purchase the latest in-depth Hepatitis D Virus (HDV) Infection Market Report @ https://www.absolutemarketsinsights.com/checkout?id=1087

Global Hepatitis D Virus (HDV) Infection Market:
• By Clinical Trails
o Pre-Clinical and Phase I
o Phase II
o Phase III
• By Clinical Entities
o Acute HBV/HDV coinfection
o Acute HDV superinfection of a Chronic HBV carrier
o Chronic HDV infection
• By Age
o Below 20 years
o 21 – 35 years
o 36 – 50 Years
o Above 50
• By Application
o Hospitals
o Specialty Clinics
o Research Centers
• By Region
o North America
 U.S.
 Canada
 Mexico
 Rest of North America
o Europe
 France
 The UK
 Spain
 Germany
 Italy
 Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
 Benelux Union
• Belgium
• The Netherlands
• Luxembourg
 Rest of Europe
o Asia Pacific
 China
 Japan
 India
 New Zealand
 Australia
 South Korea
 Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
 Rest of Asia Pacific
o Middle East & Africa
 Saudi Arabia
 UAE
 Egypt
 Kuwait
 South Africa
 Rest of Middle East & Africa
o Latin America
 Brazil
 Argentina
 Rest of Latin America

Browse more trending reports by Absolute Markets Insights:

Immunotherapy Drugs Market: Global immunotherapy drugs market was valued at US$ 133.43 Bn in 2020 growing at a CAGR of 10.9% over the forecast period (2021 – 2029): https://www.absolutemarketsinsights.com/reports/Global-Immunotherapy-Drugs-Market-2021---2029-919

Global Platelet Rich Plasma Market- Global platelet rich plasma market was valued at US$ 578.23 Mn in 2020 growing at a CAGR of 15.65% over the forecast period (2021 – 2029)-https://www.absolutemarketsinsights.com/reports/Global-Platelet-Rich-Plasma-Market-2021---2029-918

Vitamin Supplements For Immune Health Market- The global vitamins supplements market is anticipated to grow from US$ 100.51 billion in 2021 to $161.56 billion in 2028 at a CAGR of 6.1% in the forecast period-https://www.absolutemarketsinsights.com/reports/Vitamin-Supplements-for-Immune-Health-Market-2021---2029-917

About Us:
Absolute Markets Insights assists in providing accurate and latest trends related to consumer demand, consumer behavior, sales, and growth opportunities, for the better understanding of the market, thus helping in product designing, featuring, and demanding forecasts. Our experts provide you the end-products that can provide transparency, actionable data, cross-channel deployment program, performance, accurate testing capabilities and the ability to promote ongoing optimization.
From the in-depth analysis and segregation, we serve our clients to fulfill their immediate as well as ongoing research requirements. Minute analysis impact large decisions and thereby the source of business intelligence (BI) plays an important role, which keeps us upgraded with current and upcoming market scenarios.

Contact Us:
Contact Name: Shreyas Tanna
Company: Absolute Markets Insights
Email Id: sales@absolutemarketsinsights.com
Phone: IN +91-7400-24-24-24, US +1-510-420-1213
Website: www.absolutemarketsinsights.com

Shreyas Tanna
Absolute Markets Insights
+1 510-420-1213
sales@absolutemarketsinsights.com
Visit us on social media:
Facebook
Twitter
LinkedIn